Arrowstreet Capital
TCRT icon

Arrowstreet Capital’s Alaunos Therapeutics TCRT Stock Holding History

Arrowstreet Capital’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-871
Closed -$617K – 2111
2019
Q4 		$617K Buy
+871
New +$599K ﹤0.01% 1453
2016
Q1 		– Sell
-4,005
Closed -$4.99M – 1523
2015
Q4 		$4.99M Buy
+4,005
New +$6.62M 0.02% 545
2015
Q3 		– Sell
-2,036
Closed -$3.66M – 1493
2015
Q2 		$3.66M Buy
+2,036
New +$3.16M 0.02% 500

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital's TCRT Position: Q1 2020 in Review

Arrowstreet Capital sold out of Alaunos Therapeutics (TCRT) in Q1 2020, closing a stake of 871 shares — an estimated $617K sold.

Arrowstreet Capital first reported a position in TCRT in Q2 2015 and held it in 3 quarters. The position peaked at $4.99M in Q4 2015. 146 funds tracked by Wall St. Rank hold TCRT as of Q1 2020.

  • Arrowstreet Capital reported no remaining Alaunos Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 871 Alaunos Therapeutics shares in Q1 2020, an estimated $617K.
  • Arrowstreet Capital first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 3 quarters.
  • Arrowstreet Capital's Alaunos Therapeutics position peaked at $4.99M in Q4 2015.
  • 146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2020.

Based on Arrowstreet Capital's 13F filing for Q1 2020, filed 15 May 2020.